Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
- Registration Number
- NCT03707171
- Lead Sponsor
- Third Military Medical University
- Brief Summary
Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health and quality of life of the elderly. Prevention and treatment measures for cognitive decline in persons with T2DM has not been well studied.
Glucagon-like peptide-1 (GLP-1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial L-cells.GLP-1 enhances glucose-dependent secretion of insulin,inhibits glucagon secretion, slows gastric emptying and reduces food intake. Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM. The effect on BMI,waist circumference, hip circumference, waist-to-hip ratio,fasting plasma glucose，glycosylated hemoglobin,blood lipids and cognitive function were measured to explore the effects of liraglutide in patients with T2DM.
The overall goal of this study is to explore the effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and make further contribution to the improvement of cognitive function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- Type 2 diabetes。
- Type 2 diabetes with acute diabetic complications.
- Type 1 diabetes.
- Other diseases affecting cognitive function (congenital dementia,brain trauma,severe heart dysfunction,severe kidney dysfunction,severe lung dysfunction,epilepsy,severe hypoglycemic coma,cerebrovascular disease,ischemic heart disease,etc).
- Alcohol abuse,mental illness and psychoactive substance abuse.
- History of thyroid disease.
- Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo placebo 12 weeks of Placebo treatment at adjusting dose Drug:Placebo Liraglutide Liraglutide 12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
- Primary Outcome Measures
Name Time Method Changes of cognitive function assessed by cognitive function scale after 12 weeks. Baseline,4weeks,8weeks，12weeks(End of Trial) The cognitive function will be calculated from performance on the following measures: (1)Digit Span Test(DST);(2) Rey Auditory Verbal Learning(RAVL);(3) Long-Delay Free Recall(LDFR);(4) Trail Making Test(TMT);(5) Animal Naming Test(ANT);(6) Clock Drawing Test(CDT);(7)Minimum Mental State Examination(MMSE);(8)Memory and executive screening(MES);(8)functional near-infrared spectroscopy.
- Secondary Outcome Measures
Name Time Method Changes of systolic blood pressure and diastolic blood pressure Baseline,4weeks,8weeks，12weeks(End of Trial) Change of systolic blood pressure and diastolic blood pressure compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of fasting plasma glucose Baseline,4weeks,8weeks，12weeks(End of Trial) Change of fasting plasma glucose compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of HbA1c Baseline,4weeks,8weeks，12weeks(End of Trial) Change of HbA1c compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of lipid profile Baseline,4weeks,8weeks，12weeks(End of Trial) Change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of liver enzymes Baseline,4weeks,8weeks，12weeks(End of Trial) Change of liver enzymes (ALT, AST in IU/L) compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of kidney function Baseline,4weeks,8weeks，12weeks(End of Trial) Change of kidney function（serum creatinine in umol/L、eGFR in ml/min） compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of CRP Baseline,4weeks,8weeks，12weeks(End of Trial) Change of CRP compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of Body mass index(BMI) Baseline,4weeks,8weeks，12weeks(End of Trial) Change of Body mass index(BMI) compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of waist circumference Baseline,4weeks,8weeks，12weeks(End of Trial) Change of waist circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of hip circumference Baseline,4weeks,8weeks，12weeks(End of Trial) Change of hip circumference compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Change of waist-to-hip ratio Baseline,4weeks,8weeks，12weeks(End of Trial) Change of waist-to-hip ratio compared with baseline, and between the intervention and control group at the end of the study (12 weeks)
Trial Locations
- Locations (1)
The third hospital affiliated to the Third Military Medical University
🇨🇳Chongqing, Chongqing, China